Sanofi

CAC 40Health careSANFR0000120578

A. is a French multinational pharmaceutical and healthcare company headquartered in Paris.

Filings

267 filings

All Inside information267 Share buyback113 Voting rights and capital36 Earnings release9 Half-year financial report2 Universal registration document2 Threshold crossing1 Annual financial report1

04/08/2026
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Inside informationFR
30/07/2026
Press Release: Sanofi’s half-year financial report for 2026
Inside informationFR
21/07/2026
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
Inside informationFR
10/07/2026
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Inside informationFR
01/07/2026
Communiqué de presse : Mise en ligne du document «Q2 2026 aide-mémoire »
Inside informationFrench
30/06/2026
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Inside informationFR
25/06/2026
Press Release: Sanofi Foundation opens new chapter centered on future generations
Inside informationFR
23/06/2026
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
Inside informationFR
23/06/2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Inside informationFR
22/06/2026
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Inside informationFR
19/06/2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Inside informationFR
19/06/2026
Communiqué de presse : Sanofi et HEC Paris lancent la « Sanofi MBA Life Sciences Scholarship » pour accompagner les futurs leaders de la santé
Inside informationFrench
13/06/2026
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Inside informationFR
10/06/2026
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Inside informationFR
08/06/2026
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Inside informationFR
04/06/2026
Press Release: Sanofi launches 2026 global employee stock purchase plan
Inside informationFR
28/05/2026
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Inside informationFR
18/05/2026
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Inside informationFR
29/04/2026
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Inside informationFR
24/04/2026
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Inside informationFR
24/04/2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Inside informationFR
22/04/2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Inside informationFR
22/04/2026
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Inside information
22/04/2026
Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants
Inside informationFrench
22/04/2026
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis
Inside informationFrench
22/04/2026
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Inside information
18/04/2026
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
Inside informationFR
13/04/2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Inside informationFR
08/04/2026
Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents
Inside informationFR
07/04/2026
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
Inside informationFR
31/03/2026
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
Inside informationFR
28/03/2026
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Inside informationFR
27/03/2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
Inside informationFR
24/03/2026
Press release: Availability of the Q1 2026 aide-mémoire
Inside informationFR
24/03/2026
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Inside informationFR
18/03/2026
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Inside informationFR
05/03/2026
Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
Inside informationFR
04/03/2026
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
Inside informationFR
02/03/2026
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Inside informationFR
27/02/2026
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Inside informationFR
24/02/2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Inside informationFR
17/02/2026
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Inside informationFR
17/02/2026
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Inside informationFR

About

ISIN: FR0000120578
Ticker: SAN
LEI: 549300E9PC51EN656011
Sector: Health care
Founded: 2004
Employees: 106,566
Country of registration: FR
Last filing: 04/08/2026, 07:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive